1. Pink Sheet
  2. >>Legal & IP

How Comprehensive Do IPR Decisions Have To Be?

 
• By Brenda Sandburg

Supreme Court to consider whether Patent Trial and Appeal Board must address all patent claims challenged in an inter partes review petition.

While it's not the headliner inter partes review case before the US Supreme Court, the outcome of SAS Institute v. Matal could impact the way patent challenge proceedings are handled by the patent office and what claims can be litigated in district court.

The court will determine whether final written decisions by the US Patent and Trademark Office's Patent Trial and Appeal must...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By Vibha Sharma

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.

Business Background Of New CDER Director George Tidmarsh

 
• By Bridget Silverman

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.

‘Prescription Drugs Are Not Golf Balls’: FTC/DoJ Solicit Clashing Opinions On Patents

 
• By Urtė Fultinavičiūtė

Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?